Dimensional Fund Advisors LP lowered its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 6.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 600,719 shares of the company’s stock after selling 39,141 shares during the period. Dimensional Fund Advisors LP owned approximately 1.68% of Medpace worth $83,618,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors also recently bought and sold shares of MEDP. Marshall Wace LLP bought a new position in Medpace during the 1st quarter worth approximately $99,000. FMR LLC increased its position in shares of Medpace by 6,709.3% in the 1st quarter. FMR LLC now owns 37,247 shares of the company’s stock valued at $2,196,000 after buying an additional 36,700 shares in the last quarter. Cubist Systematic Strategies LLC raised its stake in Medpace by 166.9% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 35,237 shares of the company’s stock worth $3,938,000 after buying an additional 22,034 shares during the period. California State Teachers Retirement System lifted its holdings in Medpace by 0.3% during the third quarter. California State Teachers Retirement System now owns 41,283 shares of the company’s stock worth $4,613,000 after acquiring an additional 113 shares in the last quarter. Finally, Voloridge Investment Management LLC bought a new stake in shares of Medpace in the third quarter worth about $4,997,000. Institutional investors own 74.44% of the company’s stock.
MEDP has been the subject of a number of research reports. Truist increased their target price on Medpace from $135.00 to $180.00 in a research note on Wednesday, February 17th. Zacks Investment Research lowered shares of Medpace from a “buy” rating to a “sell” rating in a report on Tuesday, February 23rd. Finally, Credit Suisse Group upped their target price on shares of Medpace from $178.00 to $181.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 23rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $140.67.
Shares of MEDP opened at $173.80 on Tuesday. The stock has a market capitalization of $6.26 billion, a price-to-earnings ratio of 53.15 and a beta of 1.35. Medpace Holdings, Inc. has a 12 month low of $73.62 and a 12 month high of $177.12. The firm has a fifty day simple moving average of $163.38 and a 200 day simple moving average of $140.09.
Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Sunday, February 14th. The company reported $1.35 EPS for the quarter, topping the Zacks’ consensus estimate of $1.24 by $0.11. Medpace had a net margin of 13.87% and a return on equity of 17.67%. The company had revenue of $259.68 million during the quarter, compared to the consensus estimate of $246.41 million. On average, equities research analysts predict that Medpace Holdings, Inc. will post 4 EPS for the current year.
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Featured Story: Profit margin is different from the revenue
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.